Overall, reported objective response rates (ORR) with anti-PD-(L)1 monotherapy range from 13% to 16% in head and neck squamous cell carcinoma (HNSCC), 20%–21% in urothelial carcinoma (UC), 19%–55% in non–small cell lung cancer (NSCLC), and 21%–40% in melanoma (2). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.